264 related articles for article (PubMed ID: 10891904)
1. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
Peltola J; Kulmala P; Isojärvi J; Saiz A; Latvala K; Palmio J; Savola K; Knip M; Keränen T; Graus F
Neurology; 2000 Jul; 55(1):46-50. PubMed ID: 10891904
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
3. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study.
Kwan P; Sills GJ; Kelly K; Butler E; Brodie MJ
Epilepsy Res; 2000 Dec; 42(2-3):191-5. PubMed ID: 11074191
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.
Dinkel K; Meinck HM; Jury KM; Karges W; Richter W
Ann Neurol; 1998 Aug; 44(2):194-201. PubMed ID: 9708541
[TBL] [Abstract][Full Text] [Related]
5. Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab).
Vianello M; Giometto B; Vassanelli S; Canato M; Betterle C; Mucignat C
Exp Neurol; 2006 Dec; 202(2):514-8. PubMed ID: 16890938
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy.
Liimatainen S; Peltola M; Sabater L; Fallah M; Kharazmi E; Haapala AM; Dastidar P; Knip M; Saiz A; Peltola J
Epilepsia; 2010 May; 51(5):760-7. PubMed ID: 19817821
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients.
Errichiello L; Perruolo G; Pascarella A; Formisano P; Minetti C; Striano S; Zara F; Striano P
J Neuroimmunol; 2009 Jun; 211(1-2):120-3. PubMed ID: 19428124
[TBL] [Abstract][Full Text] [Related]
8. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
10. Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy.
Tizazu E; Ellis CA; Reichert J; Lancaster E
Seizure; 2020 Aug; 80():38-41. PubMed ID: 32512284
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in the occurrence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies.
Davenport C; Radford PM; Al-Bukhari TA; Lai M; Bottazzo GF; Todd I
Clin Exp Immunol; 1998 Mar; 111(3):497-505. PubMed ID: 9528889
[TBL] [Abstract][Full Text] [Related]
12. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome.
Butler MH; Solimena M; Dirkx R; Hayday A; De Camilli P
J Exp Med; 1993 Dec; 178(6):2097-106. PubMed ID: 8245784
[TBL] [Abstract][Full Text] [Related]
13. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity.
Costa M; Saiz A; Casamitjana R; Castañer MF; Sanmartí A; Graus F; Jaraquemada D
Clin Exp Immunol; 2002 Sep; 129(3):471-8. PubMed ID: 12197888
[TBL] [Abstract][Full Text] [Related]
14. Anti-GAD antibodies in a cohort of neuropsychiatric patients.
Vinke AM; Schaper FLWVJ; Vlooswijk MCG; Nicolai J; Majoie MHJM; Martinez Martinez P; Hoffmann C; Damoiseaux JGMC; Rouhl RPW
Epilepsy Behav; 2018 May; 82():25-28. PubMed ID: 29579551
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.
Gresa-Arribas N; Ariño H; Martínez-Hernández E; Petit-Pedrol M; Sabater L; Saiz A; Dalmau J; Graus F
PLoS One; 2015; 10(3):e0121364. PubMed ID: 25774787
[TBL] [Abstract][Full Text] [Related]
16. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic usefulness of glutamic acid decarboxylase antibodies in stiff-man syndrome].
Saiz A; Arias M; Fernández-Barreiro A; Mínguez A; Casamitjana R; Tolosa E; Graus F
Med Clin (Barc); 1998 Mar; 110(10):378-81. PubMed ID: 9567281
[TBL] [Abstract][Full Text] [Related]
18. Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus.
Szűcs A; Barcs G; Winkler G; Soós Z; Folyovich A; Kelemen A; Várallyay P; Kamondi A
Ideggyogy Sz; 2014 Jul; 67(7-8):269-71. PubMed ID: 25509368
[TBL] [Abstract][Full Text] [Related]
19. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
Daw K; Ujihara N; Atkinson M; Powers AC
J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
[TBL] [Abstract][Full Text] [Related]
20. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Vulliemoz S; Vanini G; Truffert A; Chizzolini C; Seeck M
J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):187-9. PubMed ID: 17229747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
